Michael Weiss

Mr. Weiss is a member of Cyprium’s Board of Directors and Executive Vice Chairman, Strategic Development, of Cyprium’s parent company, Fortress Biotech, where he also serves as Co-Vice Chairman of its Board of Directors. In addition to his roles at Fortress, Mr. Weiss is Executive Chairman, President and CEO of TG Therapeutics, Inc. (NASDAQ: TGTX), a publicly traded biotechnology company that he co-founded in 2011 to focus on the acquisition, development and commercialization of drugs for the treatment of B-cell malignancies, and is Co-Portfolio Manager and Partner at Opus Point Partners Management, LLC. Previously, Mr. Weiss was Chairman and CEO of Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), where he led efforts to acquire and develop its lead drug Zerenex, and executed a strategic alliance for Zerenex with JT Tobacco, Inc., and Torii Pharmaceutical Co., Ltd., totaling more than $100 million. Mr. Weiss began his career as a lawyer at Cravath, Swaine & Moore LLP in New York City. He earned a J.D. from Columbia University Law School and a B.S. in finance from The State University of New York at Albany.

Cyprium was founded by Dr. Rosenwald, Dr. Yam and Mr. Weiss in 2017.